France Fines Novo Nordisk and Eli Lilly €1.7m Over GLP-1 Ad Campaigns

Novo Nordisk and Eli Lilly are facing direct regulatory consequences in France following fines totalling €1.7 million imposed over advertising campaigns for their respective GLP-1 receptor agonists, Wegovy and Mounjaro. For regulatory affairs teams operating across EU markets, the enforcement action signals that high commercial demand for anti-obesity therapies will not insulate manufacturers from pharmaceutical advertising compliance obligations.

French authorities levied the fines specifically in response to promotional activity tied to Mounjaro (tirzepatide, Eli Lilly) and Wegovy (semaglutide, Novo Nordisk), two of the highest-profile anti-obesity medicines currently on the market. The action underscores that as GLP-1 therapies attract unprecedented patient and media attention, regulators are applying heightened scrutiny to how these products are communicated to the public and healthcare professionals alike.

For regulatory affairs leads, the case is a practical reminder that advertising compliance frameworks must keep pace with commercial momentum. EU pharmaceutical advertising is governed by Directive 2001/83/EC, which restricts direct-to-consumer promotion of prescription medicines and sets clear requirements for promotional materials directed at healthcare professionals. Where campaigns for high-demand products expand rapidly across channels, the risk of regulatory exposure increases proportionally. Teams should audit current promotional materials, approval workflows, and medical-legal-regulatory sign-off processes against applicable national transpositions of EU advertising law.

Source: This article is based on reporting by Pharmaceutical Industry News (EIN Presswire, published 4 May 2026). The source article contained limited detail; no quotes, regulatory body names, or breakdown of individual fines per company were available for attribution. All regulatory framework references reflect established EU and French pharmaceutical law and are provided as editorial context.